Table 1.
Baseline Clinical and Demographic Features
| Whole Cohort | |
|---|---|
| Number | 1073 |
| Females N (%) |
698 (65 %) |
| Age Years |
58 (±14) |
| BMI BMI >30 N (%) |
28 (±6.3) 358 (33 %) |
| Alcohol Excessa Males N (%) Females |
31 (8 %) 37 (5 %) |
| Current Smoker N (%) |
286 (27 %) |
| Rheumatoid Factor Positive N (%) |
772 (72 %) |
| Anti-CCP Antibody Positive N (%) |
659 (61 %) |
| Symptom duration until diagnosisb, days | 163 (IQR 97–323) |
| DAS28 | 4.74 (±1.34) |
| 28 Swollen Joint Count | 7 (±6) |
| 28 Tender Joint Count | 8 (±7) |
| Patient Global 100mmVAS | 52 (±28) |
| Physician Global 100 mm VAS | 45 (±24) |
| Pain 100 mm VAS | 52 (±28) |
| HAQ | 1.17 (±0.8) |
| EQ5D Index | 0.51 (±0.32) |
| HAD Anxiety Scale ≥11 N (%) |
208 (19 %) |
| HAD Depression Scale ≥11 N (%) |
138 (13 %) |
| ESRb | 22 (IQR 12–41) |
| CRPb | 12 (IQR 5–33) |
| Commenced Methotrexate N (%) |
810 (75 %) |
| Modified Sharp Score – Hands and Feet Erosion scoreb Joint space narrowing scoreb Total Sharp Scoreb |
0 (IQR 0–3.0) 0 (IQR 0–4.0) 2 (IQR 0–7.0) |
Values are mean (SD) unless otherwise stated
aAlcohol excess – defined as greater than recommended weekly intake; males >21units/week, females >14units/week
bMedian (IQR)